Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.

× No keyword cloud information.

17 in total

Review 1. Chimeric antigen receptor T cell therapies for acute myeloid leukemia.

Authors: Bin Gu; Jianhong Chu; Depei Wu
Journal: Front Med Date: 2020-12-01 Impact factor: 4.592

Review 2. Mouse models in hematopoietic stem cell gene therapy and genome editing.

Authors: Stefan Radtke; Olivier Humbert; Hans-Peter Kiem
Journal: Biochem Pharmacol Date: 2019-11-06 Impact factor: 5.858

Review 3. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.

Authors: Salvatore Fiorenza; Cameron J Turtle
Journal: BioDrugs Date: 2021-04-07 Impact factor: 5.807

4. Pseudogene-Mediated Gene Conversion After CRISPR-Cas9 Editing Demonstrated by Partial CD33 Conversion with SIGLEC22P.

Authors: Benjamin C Shaw; Steven Estus
Journal: CRISPR J Date: 2021-09-23

5. Efficient polymer nanoparticle-mediated delivery of gene editing reagents into human hematopoietic stem and progenitor cells.

Authors: Rkia El-Kharrag; Kurt E Berckmueller; Ravishankar Madhu; Margaret Cui; Gabriela Campoy; Heather M Mack; Carl B Wolf; Anai M Perez; Olivier Humbert; Hans-Peter Kiem; Stefan Radtke
Journal: Mol Ther Date: 2022-02-28 Impact factor: 12.910

6. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.

Authors: Priyanka Nair-Gupta; Michael Diem; Dara Reeves; Weirong Wang; Robert Schulingkamp; Katrin Sproesser; Bethany Mattson; Bradley Heidrich; Mark Mendonça; Jocelin Joseph; Jocelyn Sendecki; Brad Foulk; Gerald Chu; Damien Fink; Qun Jiao; Sheng-Jiun Wu; Kathryn Packman; Yusri Elsayed; Ricardo Attar; François Gaudet
Journal: Blood Adv Date: 2020-03-10

Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.

Review 1. Chimeric antigen receptor T cell therapies for acute myeloid leukemia.

Review 2. Mouse models in hematopoietic stem cell gene therapy and genome editing.

Review 3. CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.

4. Pseudogene-Mediated Gene Conversion After CRISPR-Cas9 Editing Demonstrated by Partial CD33 Conversion with SIGLEC22P.

5. Efficient polymer nanoparticle-mediated delivery of gene editing reagents into human hematopoietic stem and progenitor cells.

6. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.

7. In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model.

Review 8. CRISPR/Cas9 for the treatment of haematological diseases: a journey from bacteria to the bedside.

9. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.

Review 10. Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer.